Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Rational Analyst -- Ignore unavailable to you. Want to Upgrade?

To: HeyRainier who wrote (690)	4/20/1998 9:34:00 PM
From: majormember	Respond to of 1720

[SNRS & Disney] Rainier, What SNRS shares to an extent with Disney is the power to dream. While Disney represents a magical place,whether by movies or theme park, SNRS represents another kind of magic. Imagine, you walk into a Dr's office wearing glasses and after a painless, brief procedure you leave the office without your glasses. For those baby boomers needing glasses for the first time, that is magical. Disneyworld to a child is magical. Is it possible to TA with the same degree of accuracy these life altering experiences with a waste disposal co's revenue. Add to that the S & P report that advances the view of a $2 billion dollar market at 90% margin, and it doesn't take an MBA to realize this stock is undervalued. Miracle cures or drugs that appear to improve the quality of life will beat internet stocks every day of the week; at least until earnings (or lack thereof) come out. Until they do, everyone is buying the dream. Add to that VISX blowout earnings which validates high premiums and brings renewed interest to eye co. stocks. Lastly, with Nasdaq listing brings analysts and funds who will see the potential market SNRS has a monopoly on. Determine your own price upon FDA approval. VISX and BEAM leapt past $40. I'd like to know why SNRS, with a better market model and the public's acceptance of eye laser procedures, could not better $40 upon FDA approval... Best wishes, Skane